cv 3988 has been researched along with tcv 309 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imura, Y; Kawamura, M; Nishikawa, K; Takatani, M; Terashita, Z; Tsushima, S | 1 |
| Okano, S; Tagawa, M; Urakawa, N | 1 |
| Johnston, JM; Kanzaki, H; Matsubara, T; Matsuoka, S; Okada, H; Sanezumi, M; Yasuda, K | 1 |
3 other study(ies) available for cv 3988 and tcv 309
| Article | Year |
|---|---|
Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Topics: Anaphylaxis; Animals; Azepines; Furans; Hemolysis; Humans; Hypotension; Isoquinolines; Male; Microsomes; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridinium Compounds; Rabbits; Rats; Rats, Inbred Strains; Shock, Septic; Tetrahydroisoquinolines; Triazoles | 1992 |
Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
Topics: Animals; Dogs; Escherichia coli; Isoquinolines; Lipopolysaccharides; Lung; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation Inhibitors; Pulmonary Edema; Pulmonary Surfactants; Pyridinium Compounds; Shock, Septic; Tetrahydroisoquinolines | 1995 |
Platelet-activating factor (PAF) and PAF acetylhydrolase activity in rat uterus and placenta during the late stages of pregnancy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Biological Assay; Female; Isoquinolines; Phospholipases A; Phospholipid Ethers; Placenta; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy, Animal; Pyridinium Compounds; Rabbits; Rats; Rats, Wistar; Reference Values; Tetrahydroisoquinolines; Time Factors; Uterus | 1997 |